0001104659-23-069912.txt : 20230609 0001104659-23-069912.hdr.sgml : 20230609 20230609161206 ACCESSION NUMBER: 0001104659-23-069912 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230607 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fernandes Peter CENTRAL INDEX KEY: 0001642618 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36845 FILM NUMBER: 231005384 MAIL ADDRESS: STREET 1: PERRYVILLE III CORPORATE PARK STREET 2: 53 FRONTAGE ROAD, SUITE 301 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bellerophon Therapeutics, Inc. CENTRAL INDEX KEY: 0001600132 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473116175 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302 CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-574-4770 MAIL ADDRESS: STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302 CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: Bellerophon Therapeutics LLC DATE OF NAME CHANGE: 20140213 4 1 tm2318251-8_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-06-07 0 0001600132 Bellerophon Therapeutics, Inc. BLPH 0001642618 Fernandes Peter 20 INDEPENDENCE BLVD. SUITE 402 WARREN NJ 07059 0 1 0 0 See Remarks 0 Stock Options (Right to Buy) 0.8264 2023-06-07 4 A 0 100000 0 D 2033-06-07 Common Stock 100000 100000 D This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023. This option vests in 16 quarterly installments commencing on the date hereof. Chief Executive Officer, Principal Financial and Accounting Officer /s/ Peter Fernandes 2023-06-09